Summary Somatostatin analogues may be useful novel agents in the systemic treatment of advanced colorectal cancer, as somatostatin inhibits proliferation in a wide variety of cell types. Here, we report the expression profiles of somatostatin receptor mRNAs in 32 pairs of malignant and normal colonic epithelia. Receptor subtype 2 (hSSTR2) mRNA was detected throughout nearly 90% of both malignant and normal tissue by reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization. Subtype 5 (hSSTR5) mRNA was detected in 46% and 45% of tumour and mucosal samples respectively, but in 75% (9/12) of early-stage tumours (tubulovillous adenomas, Dukes' A and B) compared with 31% (5/16) of late-stage tumours (Dukes' C and 'D' tumours), 0.05>P>0.025 (X2 with Yates' correction). There was also reduced expression of hSSTR5 in samples of metastatic tumour (11%, 1/9) compared with all tumour samples (56%, 18/32) 0.025>P>0.01 (X2 with Yates' correction). Other hSSTRs (1, 3 and 4) were expressed infrequently. Thus, hSSTR2 expression is retained after malignant transformation in colonic epithelium and, although it may potentially be a target for antiproliferative therapy, its ubiquitous expression militates against this. hSSTR5 warrants investigation as a tumour suppressor.
Colorectal cancer is one of the major causes of cancer-related mortality in the western world, accounting for 12% of all cancer deaths annually in England and Wales and the USA (Cancer Research Council factsheet 1, 1990 ; NIH Consensus Conference, 1990) . Regrettably, there has been no major improvement in survival in the last 40 years, despite advances in surgery and systemic therapy (Cancer Research Council factsheet 18, 1993) .
As many patients present with disease at an advanced stage, there is an urgent need for the development of systemic therapies, which improve both quality of life and survival in patients with late-stage tumours. One such treatment strategy may involve the use of somatostatin analogues. Somatostatin was initially isolated as a growth hormone release-inhibiting factor and has subsequently been found to be a pan-inhibitory peptide, which inhibits proliferation in a wide variety of cell types, even following malignant transformation (Patel et al, 1981) . There is evidence that this antiproliferative activity may be caused by a number of mechanisms, including inhibition of release of stimulatory systemic hormones and growth factors (Patel et al, 1981) , inhibition of angiogenesis (Woltering et al, 1990) , immunomodulation (Partsch et al, 1992) and direct action through high-affinity, cell-surface receptors (Pagliacci et al, 1991; Buscail et al, 1994) . Five highaffinity, cell-surface somatostatin receptors of the seven-transmembrane, G-protein-coupled type have been identified and their genes sequenced (Yamada et al, 1992a (Yamada et al, , b, 1993 Rohrer et al, 1993; O'Carroll et al, 1993) . They couple to G-protein a subunits, which variously inhibit the activity of adenyl cyclase (Gal/2), prevent intracellular calcium rises (GaO) and may also stimulate the activity of protein phosphatases (Buscail et al, 1995) , leading to the abrogation of intracellular stimulatory signals and transmodulation of tyrosine kinase-type receptors, for example, the epidermal growth factor receptor (Pinski et al, 1994) . The receptor subtypes also have different biochemical characteristics, including variable binding affinities for somatostatin 14 (SS14), somatostatin 28 (SS28), which is involved in the regulation of colonic motility (Bitar and Kothary, 1994) , and synthetic analogues (Raynor et al, 1993; Lamberts et al, 1996) . Subtype 5 is the only receptor that has a higher relative binding affinity for SS28 than SS14 (O'Carroll et al, 1993) . Thus, the effect of somatostatin or its analogues on a tissue will depend on both the receptor subtype expressed and on signalling pathway recruitment.
Previous studies on somatostatin receptor expression have detected subtypes 1,2 and 5 in gastrointestinal tissue and cell lines (Yamada et al, 1992a, b; Eden and Taylor, 1993; O'Carroll et al, 1993) and hSSTR3 in the pancreas (Yamada et al, 1993) . However, studies of colonic tissues have yielded different results with diverse methodologies (Miller et al, 1992; Reubi et al, 1994) , and none of the methods used allow discrimination between the five receptor subtypes. In this study, we have determined hSSTR subtype gene expression in a series of matched normal and malignant colonic epithelia and metastases using the molecular biological techniques of reverse transcription-polymerase chain reaction (RT-PCR) and in situ hybridization (ISH), both of which enable the identification of receptor subtypes.
MATERIALS AND METHODS
Thirty-two colorectal cancer specimens, 31 mucosal specimens and 9 metastatic specimens (Table 1) were obtained fresh, snap frozen in liquid nitrogen and stored at -80°C. Total RNA was 18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41   76  69  76  65  70  79  64  51  82  69  74  72  71  52  50  80  67  75  68  65  50  81  81  75  86  57  58  81  68  38  81  58  72  58  58  59  38  78  67  54 57 'D' has been included to represent all samples of primary tumour in which distant metastases were present at the time of the initial resection.
In situ hybridization (ISH) was performed on ten representative matched tumour mucosa pairs and two metastases with a 148-bp digoxigenin-labelled riboprobe for hSSTR2, 222 bp for hSSTR5 and oligonucleotides specific for hSSTRI. Cryostat sections (7 gm) of the snap-frozen tumour were taken, allowed to air dry and fixed for 5 min in 4% paraformaldehyde at 4°C. They were then washed twice for 10 min in Hanks' balanced salt solution (Sigma). Sections were prehybridized in 50% deionized formamide, 0.5 M Tris, 1% sodium pyrophosphate, 2% polyvinyl pyrrolidone, 2% Ficoll, 50 mm EDTA, 0.6 M sodium chloride, 500 jg ml-' tRNA and 10% dextran sulphate (Sigma) for 1 h at 42°C. Hybridization was carried out overnight at 42°C with 500 jig ml-' riboprobe in prehybridization solution. Washing was performed with one manual wash of 2 x standard saline citrate (SSC) and two 10-min washes in 1 x SSC, including 30% formamide at 420C. Sections were then blocked in 3% bovine serum albumin (BSA) in 50 mM Tris, 150 mm sodium chloride and 2 mm magnesium chloride and 0.1% (V/V) Triton xlO0 (Sigma) for 30 min at room temperature. Table 3 and stage-specific expression in malignant tissue in Table 4 . The majority (87%) of normal mucosae and malignant tissues expressed hSSTR2. hSSTR5 was expressed in 45% of mucosal and 46% of malignant samples. The ISH technique was verified by using a mitochondrial RNA oligonucleotide cocktail probe (C21, a gift from Dr JH Pringle, Department of Pathology, University of Leicester, UK) as a positive control for tissue integrity (results not shown). Sense probes were used as negative controls for non-specific probe binding. Results of ISH using oligonucleotides for hSSTR1 were identical to PCR results, with positive staining only being observed in two samples (results not shown). Probe distribution in tumour samples was ubiquitous throughout viable malignant tissue. hSSTR2 mRNA was present throughout all malignant epithelia and was especially dense in some of the earlier stage tumours. Generally, tumour staining was more dense than mucosal staining, which appeared strongest in basal epithelial cells and some stromal cells ( Figure IA and C) . Metastases also expressed hSSTR2 mRNA in all viable malignant cells. There was no loss of hSSTR2 expression in any population of malignant cells. In contrast, hSSTR5 was expressed in only half of the tumours examined, and unstained areas were clearly visible within the sections ( Figure IE) .
DISCUSSION
The failure of conventional systemic therapies to improve the outlook for patients with advanced colorectal cancer significantly (Cancer Research Campaign factsheet 18, 1993) makes the need for alternative approaches urgent. As most patients die of surgically untreatable disease, treatments that improve length and quality of life but do not result in systemic toxicity would be valuable, even if they prove to be palliative. One such treatment strategy may involve the use of somatostatin analogues, as they have inherent antiproliferative properties and exhibit minimal toxicity (Patel et al, 1981) . As a preliminary to the rational evaluation of these agents in the treatment of patients with advanced colorectal cancer, we have mapped the distribution of somatostatin hSSTR5 is the only receptor with a higher affinity for somatostatin 28 (O'Carroll et al, 1993) , a peptide found in colonic epithelium and involved in the regulation of colonic motility (Bitar and Kotharny, 1994) . It is unclear why only a proportion of samples of normal mucosa express hSSTR5, especially since its expression is common in early neoplasms. This finding also warrants further investigation.
Using RT-PCR, we were able to demonstrate the expression of hSSTR1, 3 and 4 in colon cancer and colonic mucosa relatively infrequently. It is interesting to note that hSSTR1 expression in colonic tissue is not confined to neuroendocrine cells. In situ hybridization using probes for hSSTR1 showed that the expression, where present, was in both mucosa and cancer tissue. In the past, the hSSTR1 receptor has been described mainly in the central nervous system and endocrine tumours, so the scarcity of its expression in colorectal tissue is not surprising.
Previously, two studies have described somatostatin receptor expression in colorectal cancer specimens, the first using autoradiography and the second, membrane ligand binding. In the autoradiographic studies, the ligands used were '251[Tyr3] octreotide, which has high affinity for hSSTR2 and 5, modest affinity for hSSTR3 and virtually no affinity for hSSTR1 or 4, and['251]SS28, which binds to all receptor subtypes with high affinity but has highest affinity for hSSTR5 (Reubi et al, 1994) . The results of these studies demonstrated expression of receptors in 3/14 colorectal cancers and in all peritumoral veins. This method does not adequately distinguish between hSSTR2, 3 and 5. We have not specifically sought to look for peritumoral veins. The membranebinding studies reported by Miller et al (1992) using['251]SS14, found binding in 17/23 of colorectal cancers, although this was of low affinity; SS14 will bind to all receptor subtypes with high affinity. The frequency of expression in this study is of the same order as in our study. It may be that the low-affinity binding was previously caused by ligand catabolism as SS14 is rapidly degraded (Patel et al, 1981) , or is indicative of uncoupled receptor. Somatostatin receptor expression has previously been demonstrated by RT-PCR in human colon cancer cell lines (hSSTR1 and 2) (Eden and Taylor, 1993; Warhurst et al, 1995) and normal colonic mucosa (hSSTR1 and 2) (Warhurst et al, 1995) , but not in matched tumour/mucosal pairs. hSSTR5 expression in colon cancer cell lines or tissue has not been analysed previously.
These studies are important as they show which of the somatostatin receptors it may be possible to target in patients with colon cancer. We have identified the two receptor subtypes most commonly expressed in colon cancer: hSSTR2 and hSSTR5. hSSTR5 is only occasionally expressed by metastases, and expression in primary tumours, when present, is patchy. The hSSTR5 subtype is, therefore, unlikely to be an appropriate target for therapy. In contrast, the expression of the hSSTR2 gene is almost ubiquitous in colon cancer and this includes metastasis. In situ studies also show that its expression is homogeneous. However, these and other studies show that most cell types express the hSSTR2 Yamada et al, 1993) , hence selectivity of action is not possible.
In transfection studies, the somatostatin receptors have been shown to be coupled to a variety of signalling pathways via heterotrimeric G-protein complexes. All appear to be linked to the inhibition of adenyl cyclase (Patel et al, 1994) , but this pathway does not appear to be of primary importance in the antiproliferative activity of somatostatin. Both hSSTR2 and hSSTR1 exhibit growthinhibitory effects via tyrosine phosphatases in vitro (Leibow et al, 1989; Todisco et al, 1994; Buscail et al, 1994) and, hence, can directly antagonize the effects of growth factors, such as EGF (Vidal et al, 1994) . hSSTR5 is also linked to the inhibition of proliferation in vitro, although the mechanism appears to be the inhibition of intracellular calcium mobilization (Buscail et al, 1995) .
hSSTR2 is the receptor subtype to which the currently marketed analogue, octreotide, binds with highest affinity (Lamberts et al, 1996) . Vapreotide (RC160) and lanreotide (BIM23014) bind to hSSTR5 with higher affinity than octreotide. Lanreotide, but not vapreotide, also binds to hSSTR2 with higher affinity than octreotide, and all three analogues have a lower affinity for the other three subtypes (O'Carroll et al, 1994; Lamberts et al, 1996) . Some reports have suggested that vapreotide (RC160) is associated with tyrosine phosphatase activity but octreotide is not (Todisco et al, 1994) , although on the basis of the subtype specificity of the analogues, it is difficult to explain this. hSSTR5 has not, to date, been linked to phosphatase activity. All of these analogues have demonstrated antiproliferative activity in cell culture and xenograft studies (Singh et al, 1986; Qin et al, 1992; Radulovic et al, 1993; Stewart et al, 1994; van Eijck et al, 1994) . Some studies have been carried out using octreotide in patients with advanced gastrointestinal cancer, although the results have been contradictory: three trials failed to demonstrate clinical response to treatment (Klijn et al, 1990; Krook et al, 1993; Palmer Smith et al, 1994) . The first of these trials (Klijn et al, 1990 ), a phase II study of 34 patients with metastatic pancreatic and gastrointestinal malignancies treated with octreotide, showed no objective responses to treatment and most patients did not demonstrate disease stabilization. In the second study (Krook et al, 1993) , 260 patients with advanced colorectal cancer were randomized to receive either octreotide, 150 jig three times daily, or best supportive care. No difference in survival was demonstrated. In the final small study (Palmer Smith et al, 1994) , 12 patients with colorectal cancer were treated with octreotide, but no responses seen. These findings contrast with the most recently published study (Cascinu et al, 1995) in which patients with advanced colorectal (24 vs 22), pancreatic (16 vs 16) and gastric (15 vs 14) malignancies were randomized to octreotide or best supportive care. Although no patient achieved an objective response, median survival in the octreotide-treated group was significantly improved at 20 vs 11 weeks. The octreotide-treated group was also more likely to exhibit disease stabilization (45% vs 15%). The small numbers of patients, lack of a placebo group and the disparate conditions treated make it difficult to accept the results of this study fully. In general, the need for well-constructed studies of sufficient size is clear.
In summary, this work demonstrates that there is almost ubiquitous expression of hSSTR2 mRNA in colonic tumours. This finding lends some support to the use of potent long-acting somatostatin analogues with direct growth-inhibitory effects via the hSSTR2 receptor in patients with colon cancer. However, the widespread expression of this receptor in most cell types indicates that there is unlikely to be sufficient specificity to allow a useful, direct, anti-tumour effect, although this does not preclude somatostatin analogues from having indirect antiproliferative activity. In addition, it would be necessary first to develop methods, which confirm both the presence of receptor protein and of appropriate growth-inhibitory signalling pathways in cancer tissue, as well as transfected cell lines. hSSTR5 is not an appropriate target for the direct effects of somatostatin analogues in colon cancer, as its expression is frequently lost with tumour progression, but it warrants investigation as a tumour suppressor. ABBREVIATIONS hSSTR, human somatostatin receptor; SS 14, SS28, somatostatin 14 and 28 respectively; PCR, polymerase chain reaction; RT, reverse transcription; ISH, RNA in situ hybridization; RT-PCR, reverse transcription-polymerase chain reaction; DMSO, dimethyl sulphoxide; MMLV-RT, mouse Moloney leukaemia virus reverse transcriptase; DTT, dithiothreitol; dNTP, deoxynucleotide; SSC, standard saline citrate; BSA, bovine serum albumin.
